[Rational therapy of heart failure]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Congestive heart failure (CHF) progression remains a significant therapeutic challenge.
• Current standard CHF therapy includes diuretics and glycosides.

Observation:

• Prospective studies demonstrate that angiotensin-converting enzyme (ACE) inhibitors reduce cardiovascular and total mortality in CHF patients.
• ACE inhibitors act as vasodilators and counteract detrimental neuroendocrine system activation.
• The SOLVD-Study prevention trial showed ACE inhibitors can attenuate or halt CHF development in patients with reduced ejection fraction.

Findings:

• ACE inhibitors are established as standard therapy for CHF.
• Treatment with ACE inhibitors leads to a reduction in mortality for CHF patients.
• In patients with reduced ejection fraction post-myocardial infarction, ACE inhibitors are crucial for preventing CHF progression.

Implications:

• Optimal dosing, initiation timing, and duration of ACE inhibitor therapy require further investigation.
• ACE inhibitors are a cornerstone in managing CHF and improving cardiovascular prognosis.
• Future trials will explore potential additional benefits of beta-blockers in specific CHF patient subgroups.